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Introduction 57
The Achilles tendon is prone to damage and rupture 1 . Increased stress on tendons during 58 exercise can cause such damage in both professional and recreational athletes, typically as 59 a result of repetitive mechanical loading 2, 3, 4 . Achilles tendon pathology (ATP) can manifest as 60 either insertional or noninsertional pathologies 1, 5 . Alternatively the pathology can present as 61 partial or complete rupture 1, 5 and lead to long-term incapacitation and a reduction in physical 62 activity 1 . 63
64
A range of factors, including genetics, have been shown to increase the risk of ATP 4, [6] [7] [8] . For 65 example, genes that encode proteins with a role in maintaining the integrity of the tendon 66 extracellular matrix (ECM) have been shown to associate with ATP 4, 6, 8 . Apoptosis is a normal 67 mechanism in tendon healing to remove damaged tenocytes 9 , however, relatively little is 68 known about genetic variation within genes involved in apoptosis and the risk of ATP. 69
Previous work in this area has been limited to variants within the CASP8 (rs384129, 70 rs1045485), NOS2 (rs2779249) and NOS3 (rs1799983) genes in two cohorts from the 71 Southern Hemisphere (South Africa and Australia) 10 .
73
The TNFRSF1A gene encodes tumour necrosis factor receptor 1 (TNFR1), a cell receptor 74 that can signal apoptosis in response to the pro-inflammatory cytokine tumour necrosis 75 factor-alpha (TNF-α) 11, 12 . TNFR1 mRNA and protein have recently been identified in human 76
Achilles tendon 12 with partial or complete Achilles tendon rupture (N=23). We further recruited an additional 29 128 cases with more than one type of tendinopathy (insertional and noninsertional). Three 129 individuals originally recruited as controls later self-reported symptoms of ATP but the 130 specific type of tendinopathy for these was not obtained. Subsequent to initial diagnosis, 15 131 cases with Achilles tendinopathy went on to develop ruptures. As each subpathology 132 (insertional, non-insertional and rupture) was relatively small in number we pooled all cases 133 as having the combined condition of Achilles tendon pathology and this was the main 134 phenotype we chose to investigate. Additional association analysis on each subpathology 135 was, nevertheless, investigated but this was statistically underpowered due to the small 136 sample sizes. All participants completed a physical activity/medical history/injury 137 questionnaire. and gave written, informed consent. The study was approved by the Research 138
Ethics Committee of the University of Northampton, United Kingdom.
140
DNA was extracted from 2 mL of saliva collected using ORAGENE-DNA kits (OG-500) and 141 DNA purification was carried out using the prepIT-L2P DNA extraction kit (DNA Genotek Inc., 142
Ontario, Canada). Quantitative PCR (qPCR) reactions were run on a StepOnePlus Real-143
Time PCR System (Applied Biosystems, Foster City, California, USA) in 96-well plates, using 144 fluorescence-based TaqMan assays. The genotyping assays for the TNFRSF1A rs4149577, 145 CASP3 rs1049253 and CASP8 variants were selected from Applied Biosystems. PCR 146 reactions contained probes and primers in a mastermix containing AmpliTaq DNA 147
Polymerase Gold and 10 ng of DNA. The cycling conditions consisted of a holding phase at 148 95 °C for 10 min, followed by 40 cycles of denaturing at 95 °C for 15 s and 149
annealing/extension at 60 °C for 1 min. Quality control for our SNP genotyping consisted of 150 running both within and between plate replicates to assess for reproducibility in genotype call 151 along with the running of 4 no DNA template controls (NTC) in each qPCR run. For the copy 152 number assays, each sample was repeated in quadruplicate along with the inclusion of 153
NTCs. 154 155
For the TNFRSF1A rs4149577 and CASP3 rs1049253 SNPs, the TaqMan Genotyping 156
Assays (C_2645708_10 and C_11683739_10 respectively) contained both FAM and VIC 157 reporter dye labelled probes to discriminate between genotypes, along with ROX dye as the 158 passive reference. Genotypes were called using StepOne Software version 2.1 (Applied 159
Biosystems, Foster City, California, USA). CNV spanning intron 11 -intron 12 of the CASP8 160 gene was determined using the TaqMan Copy Number Assay Hs02601709_cn along with 161 the reference assay for RNase P. QPCR was performed as a duplex reaction and all CN 162 data were exported into CopyCaller Software version 2.0 (Applied Biosystems, Foster City, 163
California, USA) for calculation of discrete and continuous CN. CN of the target gene was 164 normalised relative to the reference RNase P gene. We used CopyCaller Software to 165 calculate confidence and z-score quality metrics. CN calls were inspected for reproducibility 166 and accepted with a z-score <1.75. To establish PCR efficiency of both assays (CASP8 and 167 
Results 193
The CON and ATP groups were similarly matched for gender, height, weight and BMI. 194
However, there was a significant difference in age (p = 0.019) between the CON (41.3 ±8 11.3, n = 122) and ATP (45.1 ± 14.2, n = 127) groups. There was a small but significant 196 difference in age between the CON and RUP groups (p=0.036). Full details of the study 197 participant characteristics (including the TEN and RUP subgroups) can be seen in Table 1 . 198
The FAM labelled TaqMan Copy Number Assay and the VIC labelled Reference Assay 199
RNase P gave PCR efficiencies of 106% and 104% respectively. We found no interaction 200 between the variants investigated and participant characteristics for the entire cohort (data 201 not shown). We also found that none of the variants investigated associated with either the Table 3 . At this locus, 4 ATP 224 and 2 CON participants were shown to have < 2 copies, while 10 ATP and 14 CON had > 2 225 copies. When we compared the distribution of discrete CN between ATP and CON groups, 226
we found no evidence of a significant difference (p = 0.219). Furthermore, there was no 227 significant difference in CN between the male ATP and the CON group (p = 0.703) nor 228 between the female ATP and CON group (p = 0.277). We also found that when we analysed 229 CN data as a continuous variable with a Mann Whitney U-test, there were no significant 230 differences between ATP and CON groups. This was also the case in gender specific 231 analyses (data not shown). 232 233
Discussion 234
The TNFRSF1A rs4149577 variant does not appear to be associated with ATP in a British 235 cohort. TNFR1 has a role in apoptosis and it is expressed at significantly higher levels in 236 as CNV. This assertion is supported by the fact that the CASP8 rs1045485 SNP is a non-253 synonymous G>C polymorphism that results in an amino acid change (Asp302His), which 254 may affect interaction with other proteins 9 . In contrast, the functional effect of altered CN at 255 the CASP8 locus we investigated is presently unknown. Secondly, the association of this 256 region of the CASP8 gene with ATP might be a population specific effect, as association with 257 the CASP8 rs1045485 SNP was reported in South African and Australian cohorts 10 and our 258 data were obtained from British Caucasians. With this in mind, we would envisage further 259 studies on this British cohort using the SNPs investigated by Nell et al (2012) to establish 260 whether they specifically associate with ATP. This would confirm or refute any population 261 difference with high resolution. An additional haplotype based association study using these 262 SNPs would also be worthwhile. 263
264
Although we did not find an association between the CASP3 rs1049253 variant and the ATP 265 group as a whole, we did observe that both genotype and allele frequency distributions 266 approached significance when male CON and male ATP were compared. Furthermore, we 267 did find a quantitative overrepresentation of the CC genotype in males with insertional 268 tendinopathy compared to male controls (data not shown). However, a detailed statistical 269 analysis of this was not possible due to the small number of males in our cohort who 270 presented with this sub-pathology, nevertheless, it does warrant further investigation. 271
272
Our study seems to exclude the TNFRSF1A rs4149577, CASP3 rs1049253 and CASP8 CN 273 loci from a role in ATP. However, we must be cautious in interpreting these findings as the 274 study has some limitations. Firstly, although our investigation was sufficiently powered to 275 detect relatively large effect sizes given the total sample size of 262, it lacked power to detect 276 associations with more modest effects. Secondly, while we found no association between 277 discrete CN calls and ATP for the CASP8 locus, we were aware that it has been suggested 278 that rounding CN data into discrete calls might introduce a degree of error 28 . However, to 279 circumvent this possible issue, we also analysed our CN data as a continuous variable and 280 found a concordant lack of association that agreed with the discrete CN findings (data not 281 shown). 282
283
To our knowledge, no previous study has investigated whether the TNFRSF1A rs4149577 284
and CASP3 rs1049253 variants were associated with ATP. Additionally, this was the first 285 study to investigate whether genomic CNV (in this case within the CASP8 locus) was a 286 possible predisposing factor for ATP. To date, studies on the genetics of ATP have been 287 conducted predominantly in South African and Australian cohorts 10, [29] [30] [31] Our study was the 288 first to investigate the effect of these variants in British-based individuals. 289
290
In conclusion, the TNFRSF1A rs4149577, CASP3 rs1049253 and CASP8 variants do not 291 associate with ATP. Although we recommend that this study be repeated in a larger cohort, 292 and where possible using cases where only each subpathology is evident, these preliminary 293 findings exclude three plausible candidate gene variants from a role in a common 294 musculoskeletal pathology. and allele frequencies between CON and ATP were analysed using a Pearson's χ 2 
or 427
Fisher's exact test. Significance was accepted when p < 0.05. 
